Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bremelanotide/PDE5 inhibitor - Palatin Technologies

Next Previous
X
Search
Drug Profile

Bremelanotide/PDE5 inhibitor - Palatin Technologies

Alternative Names: Bremelanotide/PDE5i; PDE5 inhibitor/Bremelanotide

Latest Information Update: 16 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Palatin Technologies
  • Class Cyclic peptides; Erectile dysfunction therapies; Hypothalamic hormones; Melanocyte-stimulating hormones
  • Mechanism of Action Melanocortin type 4 receptor agonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Erectile dysfunction

Most Recent Events

  • 09 Sep 2024 Palatin Technologies plans a phase III trial in Erectile dysfunction (Treatment-experienced, Combination therapy) (Parenteral, Injection) in the second half of 2025
  • 09 Sep 2024 Palatin Technologies plans a Pharmacokinetics study of Bremelanotide/PDE5 inhibitor in the first quarter of 2025
  • 20 Jun 2024 Palatin Technologies plans to file an IND application with the US FDA for Erectile dysfunction by the end of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top